Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years
1. ACHV is seeking FDA approval for cytisinicline, targeting 2026 launch. 2. HC Wainwright has initiated coverage with a Buy rating and $12 price target. 3. Cytisinicline shows greater efficacy in smoking cessation compared to existing therapies. 4. Company raised $45 million to support NDA and operational costs. 5. Analysts predict significant stock value growth in the next 12-18 months.